Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS · Real-Time Price · USD
3.940
-0.130 (-3.19%)
Aug 10, 2026, 4:00 PM EDT - Market closed

Kalaris Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-47.63-46.15-51.73-199.9-171.2-169.82
Net Income
-44.1-43.44-69.17-190.42-168.71-171.96
Earnings Per Share
-2.15-2.85-51.77-42.09-50.60-63.02
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
97.22117.981.64183.94233.8248.12
Total Debt
33.4933.5251.6227.4335.3930.07
Net Cash (Debt)
63.7384.46-49.98156.51198.41218.05
Net Cash Growth
-7.49%---21.12%-9.01%-37.27%
Net Cash Per Share
3.165.53-3.2734.5959.5379.88

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-42.51-38.37-20.67-124.45-142.05-106.32
Capital Expenditures
--0.2----0.03
Free Cash Flow
-42.51-38.57-20.67-124.45-142.05-106.35
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.